InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.47
(
-0.29%
)
Bitcoin
61,024.01
(
3.42%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 96184

Friday, 05/21/2010 7:46:55 PM

Friday, May 21, 2010 7:46:55 PM

Post# of 252939
ANDS: I’m with you—i.e. skeptical of the company’s assertion that ANA598 is one of the most attractive drug candidates in the HCV arena. To the contrary, ANA598 strikes me as a drug with a narrow therapeutic window (#msg-47087879), and it appears to be inferior to, among others, VX-222, the non-nuke from VRTX.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up